Latest News & Features
Biotechnology
The America Invents Act was signed into law in September 2011, and many biotech companies are still trying to make sense of the new legislation. Eldora Ellison and Eric Steffe consider one of the most important changes. 1 January 2012
Biotechnology
For the Biotechnology Industry Organization, key developing markets pose particular challenges in terms of
IP and also in a wider context. LSIPR spoke to Joe Damond and Lila Feisee about international affairs. 1 January 2012
Americas
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007. 1 May 2011
Big Pharma
Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled. 1 May 2011
Americas
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs. 1 May 2011
Americas
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes. 1 May 2011
Asia-Pacific
An Australian legislative bill could have grave consequences for the country’s life sciences industry and, potentially, for patients as well. Tania Obranovich explains. 1 May 2011
Generics
Natural products have been used to relieve a variety of diseases and conditions for millennia. 1 May 2011
Big Pharma
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions. 1 May 2011
Americas
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications. 1 May 2011